rebound acid hypersecretion, which might have been experienced by all treated individuals, might only trigger clinically relevant symptoms in those with pre-existing lower esophageal sphincter ...

To control their GERD symptoms, many ulcer patients needed chronic, indefinite PPI therapy, even though rebound acid hypersecretion is most prominent in patients not infected with H. pylori.

A syndrome characterized by severe peptic ulcer disease, gastric acid hypersecretion, and non-beta islet cell tumors of the pancreas was first described by Zollinger and Ellison in 1955.

Total gastrectomy is no longer necessary for managing patients with ZES because effective medical therapy (proton pump inhibitors) for the acid hypersecretion can prevent ulcer disease.